RoboCath, a French startup, found that partnering with a local corporate or distributor is the most effective way to navigate the significant cultural and business differences in markets like the US and China, rather than attempting direct expansion.
The robotic platform's success was driven by a physician-founder's focus on three core needs: being precise and efficient, being user-friendly by working with all existing third-party devices, and being affordable for hospitals.
While remote procedures are a long-term goal, the immediate drivers for robotic adoption in cardiology are more practical. They solve physicians' "awful" working conditions (radiation, physical strain) and enhance interventions with a level of precision that humans cannot achieve.
For ambitious projects like surgical robotics with long development timelines, relying solely on traditional VC is risky. RoboCath found that bringing in corporate investors provided a long-term strategic vision and reassured other shareholders, which is critical for survival.
RoboCath deliberately designed its platform to be compatible with all device brands. This open-ecosystem approach lowers the barrier to adoption, as physicians don't need to abandon their preferred tools, a key advantage over competitors who might pursue exclusive partnerships.
Even as a domain expert, RoboCath's founder advises getting a minimum viable product to market as soon as possible. The market reveals unexpected truths and challenges that can't be anticipated in development. Constant validation against reality at every step is key.